SEARCH

SEARCH BY CITATION

References

  • Albitar, M., Do, K.A., Johnson, M.M., Giles, F.J., Jilani, I., O’Brien, S., Cortes, J., Thomas, D., Rassenti, L.Z., Kipps, T.J., Kantarjian, H.M. & Keating, M. (2004) Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer, 101, 9991008.
  • Ashraf, U., Elefante, A.N., Cruz, R., Wallace, P.K., Czuczman, M.S. & Hernandez-llizaliturri, F.J. (2007) Emergence of rituximab-fludarabine resistance is associated with changes in CD20 antigen expression and improved response to alemtuzumab therapy in patients with chronic lymphocytic leukemia (CLL). Blood, 110, 612a (abstract 2054).
  • Beum, P.V., Kennedy, A.D., Williams, M.E., Lindorfer, M.A. & Taylor, R.P. (2006) The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. Journal of Immunology, 176, 26002609.
  • Byrd, J.C., Lin, T.S. & Grever, M.R. (2006) Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Seminars in Oncology, 33, 210219.
  • Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J., Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R. & Hillmen, P. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet, 370, 230239.
  • Chakrabarti, S., Mackinnon, S., Chopra, R., Kottaridis, P.D., Peggs, K., O’Gorman, P., Chakraverty, R., Marshall, T., Osman, H., Mahendra, P., Craddock, C., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. & Milligan, D.W. (2002) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 99, 43574363.
  • Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., Mahendra, P., Craddock, C., Parker, A., Hunter, A., Hale, G., Waldmann, H., Williams, C.D., Yong, K., Linch, D.C., Goldstone, A.H. & Mackinnon, S. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 99, 10711078.
  • Dearden, C.E., Matutes, E., Cazin, B., Tjonnfjord, G.E., Parreira, A., Nomdedeu, B., Leoni, P., Clark, F.J., Radia, D., Rassam, S.M., Roques, T., Ketterer, N., Brito-Babapulle, V., Dyer, M.J. & Catovsky, D. (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood, 98, 17211726.
  • Delgado, J., Thomson, K., Russell, N., Ewing, J., Stewart, W., Cook, G., Devereux, S., Lovell, R., Chopra, R., Marks, D.I., Mackinnon, S. & Milligan, D.W. (2006) Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood, 107, 17241730.
  • Dewald, G.W., Brockman, S.R., Paternoster, S.F., Bone, N.D., O’Fallon, J.R., Allmer, C., James, C.D., Jelinek, D.F., Tschumper, R.C., Hanson, C.A., Pruthi, R.K., Witzig, T.E., Call, T.G. & Kay, N.E. (2003) Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 121, 287295.
  • Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343, 19101916.
  • Elter, T., Borchmann, P., Schulz, H., Reiser, M., Trelle, S., Schnell, R., Jensen, M., Staib, P., Schinkothe, T., Stutzer, H., Rech, J., Gramatzki, M., Aulitzky, W., Hasan, I., Josting, A., Hallek, M. & Engert, A. (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. Journal of Clinical Oncology, 23, 70247031.
  • Elter, T., James, R., Wendtner, C.M., Stilgenbauer, S., Winkler, D., Ritgen, M., Hallek, M. & Engert, A. (2008) Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: first safety analysis of the CLL2L trial of the German CLL Study Group. Journal of Clinical Oncology, 26, 15S. abstr 7053.
  • Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A.P., Repp, R., Schetelig, J., Seipelt, G. & Osterborg, A. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103, 29202924.
  • Ferrajoli, A., O’Brien, S.M., Cortes, J.E., Giles, F.J., Thomas, D.A., Faderl, S., Kurzrock, R., Lerner, S., Kontoyiannis, D.P. & Keating, M.J. (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer, 98, 773778.
  • Ferrajoli, A., Wierda, W., Lapushin, R., O’Brien, S., Faderl, S., Browning, M.L. & Keating, M. (2008) Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. European Journal of Haematology, 80, 296298.
  • Gilleece, M.H. & Dexter, T.M. (1993) Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood, 82, 807812.
  • Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., Dyer, M.J. & Catovsky, D. (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leukemia Research, 22, 185191.
  • Golay, J., Manganini, M., Rambaldi, A. & Introna, M. (2004) Effect of alemtuzumab on neoplastic B cells. Haematologica, 89, 14761483.
  • Grever, M.R., Lucas, D.M., Dewald, G.W., Neuberg, D.S., Reed, J.C., Kitada, S., Flinn, I.W., Tallman, M.S., Appelbaum, F.R., Larson, R.A., Paietta, E., Jelinek, D.F., Gribben, J.G. & Byrd, J.C. (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology, 25, 799804.
  • Hale, G. (2001) The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy, 3, 137143.
  • Hale, G. & Waldmann, H. (1994) Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplantation, 13, 597611.
  • Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A.J. & Waldmann, H. (1983) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood, 62, 873882.
  • Hale, G., Dyer, M.J., Clark, M.R., Phillips, J.M., Marcus, R., Riechmann, L., Winter, G. & Waldmann, H. (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet, 2, 13941399.
  • Hale, G., Zhang, M.J., Bunjes, D., Prentice, H.G., Spence, D., Horowitz, M.M., Barrett, A.J. & Waldmann, H. (1998) Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood, 92, 45814590.
  • Heit, W., Bunjes, D., Wiesneth, M., Schmeiser, T., Arnold, R., Hale, G., Waldmann, H. & Heimpel, H. (1986) Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. British Journal of Haematology, 64, 479486.
  • Hillmen, P., Skotnicki, A.B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C. & Mayer, J. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 25, 56165623.
  • Hirst, C.L., Pace, A., Pickersgill, T.P., Jones, R., McLean, B.N., Zajicek, J.P., Scolding, N.J. & Robertson, N.P. (2008) Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. Journal of Neurology, 255, 231238.
  • Isaacs, J.D., Manna, V.K., Rapson, N., Bulpitt, K.J., Hazleman, B.L., Matteson, E.L., St Clair, E.W., Schnitzer, T.J. & Johnston, J.M. (1996) CAMPATH-1H in rheumatoid arthritis – an intravenous dose-ranging study. British Journal of Rheumatology, 35, 231240.
  • Karlsson, C., Norin, S., Kimby, E., Sander, B., Porwit, M.A., Nilsson, B., Johansson, E., Mellstedt, H., Lundin, J. & Osterborg, A. (2006) Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia, 20, 22042207.
  • Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. & Rai, K.R. (2002a) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 35543561.
  • Keating, M.J., Cazin, B., Coutre, S., Birhiray, R., Kovacsovics, T., Langer, W., Leber, B., Maughan, T., Rai, K., Tjonnfjord, G., Bekradda, M., Itzhaki, M. & Herait, P. (2002b) Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. Journal of Clinical Oncology, 20, 205213.
  • Keating, M.J., O’Brien, S., Kontoyiannis, D., Plunkett, W., Koller, C., Beran, M., Lerner, S. & Kantarjian, H. (2002c) Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leukemia & Lymphoma, 43, 17551762.
  • Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., Kennedy, B., Kipps, T., Bodey, G., Byrd, J.C., Rosen, S., Dearden, C., Dyer, M.J. & Hillmen, P. (2004) Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clinical Lymphoma, 4, 220227.
  • Kennedy, B., Rawstron, A., Carter, C., Ryan, M., Speed, K., Lucas, G. & Hillmen, P. (2002) Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood, 99, 22452247.
  • Kennedy, G.A., Seymour, J.F., Wolf, M., Januszewicz, H., Davison, J., McCormack, C., Ryan, G. & Prince, H.M. (2003) Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. European Journal of Haematology, 71, 250256.
  • Khorana, A., Bunn, P., McLaughlin, P., Vose, J., Stewart, C. & Czuczman, M.S. (2001) A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin’s lymphoma. Leukemia & Lymphoma, 41, 7787.
  • Kirchhoff, C. (1996) CD52 is the ‘major maturation-associated’ sperm membrane antigen. Molecular Human Reproduction, 2, 917.
  • Kline, J., Pollyea, D.A., Stock, W., Artz, A., Rich, E., Godley, L., Zimmerman, T., Thompson, K., Pursell, K., Larson, R.A. & Van, B.K. (2006) Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplantation, 37, 307310.
  • Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J.C., Schey, S., Mahendra, P., Morgan, G.J., Hale, G., Waldmann, H., De Elvira, M.C., Williams, C.D., Devereux, S., Linch, D.C., Goldstone, A.H. & Mackinnon, S. (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, 96, 24192425.
  • Krober, A., Seiler, T., Benner, A., Bullinger, L., Bruckle, E., Lichter, P., Dohner, H. & Stilgenbauer, S. (2002) V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood, 100, 14101416.
  • Krober, A., Bloehdorn, J., Hafner, S., Buhler, A., Seiler, T., Kienle, D., Winkler, D., Bangerter, M., Schlenk, R.F., Benner, A., Lichter, P., Dohner, H. & Stilgenbauer, S. (2006) Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 969975.
  • Lozanski, G., Heerema, N.A., Flinn, I.W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M.L., Proffitt, J.H., Lucas, D., Grever, M.R. & Byrd, J.C. (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood, 103, 32783281.
  • Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., Thomas, J., Marcus, R., Nissen, N., Poynton, C., Rankin, E., Stahel, R., Uppenkamp, M., Willemze, R. & Mellstedt, H. (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology, 16, 32573263.
  • Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P.A., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H. & Osterborg, A. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100, 768773.
  • Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S., Juliusson, G., Rosenblad, E., Tjonnfjord, G., Wiklund, T. & Osterborg, A. (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood, 101, 42674272.
  • Mone, A.P., Cheney, C., Banks, A.L., Tridandapani, S., Mehter, N., Guster, S., Lin, T., Eisenbeis, C.F., Young, D.C. & Byrd, J.C. (2006) Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia, 20, 272279.
  • Montillo, M., Tedeschi, A., Miqueleiz, S., Veronese, S., Cairoli, R., Intropido, L., Ricci, F., Colosimo, A., Scarpati, B., Montagna, M., Nichelatti, M., Regazzi, M. & Morra, E. (2006) Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 23372342.
  • Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S.M., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A. & Hillmen, P. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology, 23, 29712979.
  • Morris, E. & Mackinnon, S. (2005) Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin’s lymphoma (NHL). Transfusion Apheresis Science, 32, 7383.
  • Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G.M., Parker, A., Schey, S., Chopra, R., Hatton, C., Tighe, J., Hunter, A., Peggs, K., Linch, D., Goldstone, A. & Mackinnon, S. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104, 38653871.
  • Nguyen, D.D., Cao, T.M., Dugan, K., Starcher, S.A., Fechter, R.L. & Coutre, S.E. (2002) Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clinical Lymphoma, 3, 105110.
  • Nuckel, H., Frey, U.H., Roth, A., Duhrsen, U. & Siffert, W. (2005) Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. European Journal of Pharmacology, 514, 217224.
  • O’Brien, S.M., Gribben, J.G., Thomas, D.A., Albitar, M., Wierda, W., Ferrajoli, A., Lerner, S., Kantarjian, H.M., Kipps, T. & Keating, M.J. (2003a) Alemtuzumab for minimal residual disease in CLL. Blood, 102, 109a (abstract 371).
  • O’Brien, S.M., Kantarjian, H.M., Thomas, D.A., Cortes, J., Giles, F.J., Wierda, W.G., Koller, C.A., Ferrajoli, A., Browning, M., Lerner, S., Albitar, M. & Keating, M.J. (2003b) Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer, 98, 26572663.
  • O’Brien, S., Ravandi, F., Riehl, T., Wierda, W., Huang, X., Tarrand, J., O’Neal, B., Kantarjian, H. & Keating, M. (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood, 111, 18161819.
  • Oscier, D.G., Gardiner, A.C., Mould, S.J., Glide, S., Davis, Z.A., Ibbotson, R.E., Corcoran, M.M., Chapman, R.M., Thomas, P.W., Copplestone, J.A., Orchard, J.A. & Hamblin, T.J. (2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood, 100, 11771184.
  • Osterborg, A. & Dyer, M.J. (2001) CAMPATH-1H in the treatment of lymphoid malignancies. In: Monoclonal Antibody Therapy of Hematologic Malignancies (ed. by B.D.Cheson), pp. 135150. Darwin Scientific Publishing Ltd, Abingdon, UK.
  • Osterborg, A., Fassas, A.S., Anagnostopoulos, A., Dyer, M.J., Catovsky, D. & Mellstedt, H. (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology, 93, 151153.
  • Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D. & Mellstedt, H. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 15, 15671574.
  • Osuji, N.C., Del, G.I., Matutes, E., Wotherspoon, A.C., Dearden, C. & Catovsky, D. (2005) The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica, 90, 14351436.
  • Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcia-Conde, J., Milligan, D.W., Schey, S., Urbano-Ispizua, A., Parker, A., Leon, A., Yong, K., Sureda, A., Hunter, A., Sierra, J., Goldstone, A.H., Linch, D.C., San Miguel, J.F. & Mackinnon, S. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood, 100, 31213127.
  • Perkins, J.G., Flynn, J.M., Howard, R.S. & Byrd, J.C. (2002) Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer, 94, 20332039.
  • Rai, K.R., Freter, C.E., Mercier, R.J., Cooper, M.R., Mitchell, B.S., Stadtmauer, E.A., Santabarbara, P., Wacker, B. & Brettman, L. (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Journal of Clinical Oncology, 20, 38913897.
  • Rawstron, A.C., Kennedy, B., Evans, P.A., Davies, F.E., Richards, S.J., Haynes, A.P., Russell, N.H., Hale, G., Morgan, G.J., Jack, A.S. & Hillmen, P. (2001) Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 98, 2935.
  • Rosenwald, A., Chuang, E.Y., Davis, R.E., Wiestner, A., Alizadeh, A.A., Arthur, D.C., Mitchell, J.B., Marti, G.E., Fowler, D.H., Wilson, W.H. & Staudt, L.M. (2004) Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood, 104, 14281434.
  • Rowan, W., Tite, J., Topley, P. & Brett, S.J. (1998) Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology, 95, 427436.
  • Sayala, H.A., Moreton, P., Jones, R.A., Rawstron, A.C., O’Conner, S.J., Evans, P., Carter, A., Dearden, C., Matutes, E., Pettitt, A.R., Kennedy, D.B. & Hillmen, P. (2006) Final report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with flduarabine-refractory CLL (on behalf of the NCRI CLL Trials Subgroup). Blood, 108, 14a15a (abstract 34).
  • Stanglmaier, M., Reis, S. & Hallek, M. (2004) Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Annals of Hematology, 83, 634645.
  • Stilgenbauer, S. & Dohner, H. (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. New England Journal of Medicine, 347, 452453.
  • Stilgenbauer, S., Winkler, D., Buhler, A., Zenz, T., Groner, S., Busch, R., Hensel, M., Duhrsen, U., Finke, J., Dreger, P., Jager, U., Lengfelder, E., Trumper, L., Soling, U., Schlag, R., Hallek, M. & Dohner, H. (2007) Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG). Blood, 110, 918a (abstract 3120).
  • Tam, C.S., Wierda, W., O’Brien, S.M., Lerner, S., Abruzzo, L.V., Ferrajoli, A., Kantarjian, H.M. & Keating, M.J. (2008) The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: a study of 180 consecutive patients. Journal of Clinical Oncology, 26, 380s (May 20 suppl., abstract 7035).
  • Uppenkamp, M., Engert, A., Diehl, V., Bunjes, D., Huhn, D. & Brittinger, G. (2002) Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin’s lymphomas: a multicenter phase I/II study. Annals of Hematology, 81, 2632.
  • Waldmann, H., Polliak, A., Hale, G., Or, R., Cividalli, G., Weiss, L., Weshler, Z., Samuel, S., Manor, D. & Brautbar, C. (1984) Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet, 2, 483486.
  • Wendtner, C.M., Ritgen, M., Schweighofer, C.D., Fingerle-Rowson, G., Campe, H., Jager, G., Eichhorst, B., Busch, R., Diem, H., Engert, A., Stilgenbauer, S., Dohner, H., Kneba, M., Emmerich, B. & Hallek, M. (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia, 18, 10931101.
  • Wierda, W.G., O’Brien, S., Faderl, S., Ferrajoli, A., Ravandi-Kashani, F., Cortes, J., Giles, F., Andreeff, M., Koller, C.A., Lerner, S., Kantarjian, H. & Keating, M.J. (2006) Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood, 108, 14a (abstract 31).
  • Wierda, W.G., O’Brien, S., Ferrajoli, A., Faderl, S., Koller, C., Estrov, Z., Garcia-Manero, G., Verstovsek, S., Browning, M., Learner, S. & Keating, M. (2007) Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL. Blood, 110, 628a (abstract 628).
  • Xia, M.Q., Hale, G., Lifely, M.R., Ferguson, M.A., Campbell, D., Packman, L. & Waldmann, H. (1993) Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochemical Journal, 293, 633640.
  • Zenz, T., Ritgen, M., Dreger, P., Krober, A., Barth, T.F., Schlenk, R., Bottcher, S., Hallek, M.J., Kneba, M., Bunjes, D., Dohner, H. & Stilgenbauer, S. (2006) Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood, 108, 21272130.
  • Zinzani, P.L., Alinari, L., Tani, M., Fina, M., Pileri, S. & Baccarani, M. (2005) Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica, 90, 702703.